Collegium Pharmaceutical Inc. (COLL)
COLL trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1267565/000162828026011992/0001628280-26-011992-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | COLL on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2015 |
| SEC CIK | 0001267565 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | VA |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $780.6M |
| Net income | $62.9M |
| Operating income | $179.6M |
| Net margin | 8.1% |
| Operating margin | 23.0% |
| Revenue growth | +23.6% |
| Cash | $231.3M |
| Total assets | $1.7B |
| P/E (computed) | 12.6× |
| P/S (computed) | 1.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $144.8M cash; operating cash flow $84.5M a quarter. | Report 2026-09-30 |
| Shares outstanding | 31,075,424 (2026-10-31); 31,610,976 a year earlier; 32,610,873 three years earlier. | Cover page 2026-10-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-04 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $7.2M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $216.3M | $21.8M | $86.5M | $144.8M | $60.5M | $815.2M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $199.9M | -$15.1M | $71.3M | $129.5M | $55.0M | $808.2M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $193.5M | $14.5M | $57.1M | $268.6M | $32.6M | $796.3M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $205.4M | $17.0M | $123.0M | $231.3M | $29.0M | $780.6M | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $209.4M | $31.5M | $78.4M | $150.1M | $64.6M | $757.1M | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $188.0M | $12.0M | $72.4M | $117.3M | $64.6M | $707.0M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $177.8M | $2.4M | $55.4M | $96.2M | $64.6M | $664.3M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $181.9M | $12.5M | $84.6M | $70.6M | $64.6M | $631.4M | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2020-03-16 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEF 14A | 2026-04-07 |
Source: SEC EDGAR submissions feed, 875 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +4.6% |
| 1 month | +17.6% |
| 3 months | -10.1% |
| Year to date | -45.3% |
| 1 year | -45.4% |
| From 52-week high | -49.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IVA | Inventiva S.A. American Depository Shares | $3.32 | -9.78% | $784.5M |
| ORIC | Oric Pharmaceuticals Inc. | $7.52 | -4.33% | $779.5M |
| LXRX | Lexicon Pharmaceuticals Inc. | $1.75 | -2.23% | $779.2M |
| IRWD | Ironwood Pharmaceuticals Inc. | $4.85 | +0.41% | $802.9M |
| ARDX | Ardelyx Inc. | $3.07 | -0.65% | $771.7M |
| OBX | Obsidian Therapeutics Inc. | $12.36 | -1.59% | $763.5M |
| SNDX | Syndax Pharmaceuticals Inc. | $9.13 | -3.39% | $821.6M |
| RIGL | Rigel Pharmaceuticals Inc. | $43.73 | -1.64% | $823.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier